Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 15607362

The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy.

Ken-ichirou Yoneda·Takeshi Morii·Mie Nieda·Nobuhiko Tsukaguchi·Itsuto Amano·Haruyuki Tanaka·Hideo Yagi·Nobuhiro Narita·Hiroshi Kimura
View original source ↗Export metadata ↓

Abstract

Valpha24TCR+ CD161+ NKT (Valpha24+ NKT) cells are activated by alpha-galactosylceramide and can exert anti-tumor activity against a variety of tumor cells. In this study, we assessed the Valpha24+ NKT cell numbers in peripheral blood (PB) from 30 healthy donors and 70 patients with haematopoietic malignancy including chronic myelogenous leukemia (CML), malignant lymphoma (ML), acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). Here, we demonstrated that PB Valpha24+ NKT cell numbers were significantly decreased in all the patients with haematopoietic malignancy in comparison with that in healthy donors (P < 0.005). In particular CD4- CD8- Valpha24+ NKT cell numbers were more significantly decreased in the patients with haematopoietic malignancy (P < 0.0001).

Explore related subjects

CD4 AntigensCD8 AntigensFlow CytometryHematologic NeoplasmsHumansKiller Cells, NaturalLymphocyte CountLymphocytesReceptors, Antigen, T-Cell, alpha-betaSurvival AnalysisComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ken-ichirou Yoneda, Takeshi Morii, Mie Nieda, Nobuhiko Tsukaguchi, Itsuto Amano, Haruyuki Tanaka, Hideo Yagi, Nobuhiro Narita, Hiroshi Kimura. 2005. The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy.. https://doi.org/10.1016/j.leukres.2004.06.005

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Dynamic tradeoffs in the raft-mediated entry of human immunodeficiency virus type 1 into cells.

To initiate an infection human immunodeficiency virus type 1 (HIV-1) particles must first bind to receptors on the surface of their host cells, a process that eventually leads to fusion of viral and cellular membranes and release of the viral genome into the cytoplasm. Understanding the molecular mechanisms of these processes may enable the development of new anti-HIV strategies. Disagreement currently prevails on the role in virus entry of microdomains within the cellular plasma membrane known as lipid rafts. Experiments have suggested that lipid rafts, in their interactions with cellular receptors and viral particles, either promote or have minimal effect on viral entry. Here we develop a dynamic model for HIV-1 entry that enables us to identify and quantitatively assess tradeoffs that can arise from the clustering of receptors in rafts. Specifically, receptor clustering can be detrimental to the initiation of viral infection by reducing the probability that a virus particle finds its primary receptor, CD4. However, receptor clustering can also enable a virus particle, once bound, to rapidly form multivalent interactions with receptors and co-receptors that are required for virus-cell membrane fusion. We show how the resolution of such tradeoffs hinges on the level and spatial distribution of receptors and co-receptors on the cell surface, and we discuss implications of these effects for the design of therapeutics that inhibit HIV-1 entry.

CD4 Antigens↗
PubMed2006

The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer.

There is sufficient evidence to suggest that tumor growth elicits specific immune responses, including CD8(+) and CD4(+) T cell responses that may delay tumor growth and could potentially be harnessed to eradicate cancer. Nevertheless the frequent outcome of cancer is lethality associated with uncontrolled growth and dissemination of tumor cells. The failure of the immune response may be naturally programmed and related to a specific subpopulation of CD4(+)CD25(+) regulatory T cells, whose function is to protect us against autoimmunity. Recent investigations have shed light on the in vivo behavior and functions of these cells. It is becoming evident that a major impact of these cells is on the cytolytic action of specific CD8(+) T cells that target the tumor. Inhibition of cytotoxicity is dependent on TGF-beta signaling by the effector cells. Thus, targeting immune regulation may provide a promising approach to the immune therapy of cancer. This approach however could also have unexpected deleterious consequences, as surprising new observations indicate that regulatory T cells can also delay tumor growth by independent mechanisms that relate to their cross talk with the innate immune response to cancer.

CD4 Antigens↗